These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 318212)

  • 1. Cefoxitin for treatment of infections due to anaerobic bacteria.
    Kirby BD; Busch DF; Citron DM; Finegold SM
    Rev Infect Dis; 1979; 1(1):113-7. PubMed ID: 318212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoxitin therapy in aerobic, anaerobic, and mixed aerobic-anaerobic infections.
    LeFrock JL; Schell RF; Carr BB; Kowalsky SF; Tillotson JR
    Drug Intell Clin Pharm; 1982 Apr; 16(4):306-12. PubMed ID: 7067621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome.
    Goldstein EJ; Citron DM; Cole RE; Rangel DM; Seid AS; Ostovari MO
    Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():38-45. PubMed ID: 2120272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of therapy with cefoxitin.
    McCloskey RV; Goren RC
    Clin Ther; 1980; 3(2):66-79. PubMed ID: 7448845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefoxitin: single-agent treatment of mixed aerobic-anaerobic pelvic infections.
    Sweet RL; Ledger WJ
    Obstet Gynecol; 1979 Aug; 54(2):193-8. PubMed ID: 460753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bacteriological and clinical evaluation of cefoxitin in the treatment of infections in 39 obstetric and gynecological patients].
    Kaseki S; Mano T; Tomoda Y; Kazato S; Asai Y; Sahara K; Manba S; Maruyama T; Kasugai M; Higashide K; Sekiya H; Mizutani S; Watanabe K; Ueno K
    Jpn J Antibiot; 1983 Mar; 36(3):509-21. PubMed ID: 6876361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of piperacillin versus cefoxitin in the treatment of obstetric and gynecologic infections.
    Sweet RL; Robbie MO; Ohm-Smith M; Hadley WK
    Am J Obstet Gynecol; 1983 Feb; 145(3):342-9. PubMed ID: 6218755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cefoxitin: its role in the therapy of anaerobic infections].
    Carvalho A; Fonseca C; Falcão F; Ceia F
    Acta Med Port; 1993 Oct; 6(10):467-71. PubMed ID: 8285118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of cefoxitin vs. cefotetan against clinical isolates of Bacteroides and Prevotella species.
    Grossmeyer TJ; Farmer SG
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S353-6. PubMed ID: 8324146
    [No Abstract]   [Full Text] [Related]  

  • 10. Anaerobic infections.
    Dunkle LM
    Pediatr Ann; 1986 Jun; 15(6):446-9. PubMed ID: 3523403
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of cefoxitin in anaerobic and aerobic infections. Based on the proceedings of a symposium. June 2 and 3, 1989, Carlsbad, California.
    Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():3-56. PubMed ID: 1976645
    [No Abstract]   [Full Text] [Related]  

  • 12. In-vitro and in-vivo comparison of mezlocillin and cefoxitin.
    LeFrock JL; Molavi A; Rolston K; Smith B; Schell R; Chandrasekar P; Carr B
    J Antimicrob Chemother; 1983 May; 11 Suppl C():83-90. PubMed ID: 6352609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefoxitin plus tobramycin and clindamycin plus tobramycin. A prospective randomized comparison in the therapy of mixed aerobic/anaerobic infections.
    Nicolle LE; Harding GK; Louie TJ; Thomson MJ; Blanchard RJ
    Arch Surg; 1986 Aug; 121(8):891-6. PubMed ID: 3524511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical findings of cefoxitin in the treatment of obstetric and gynecological infections (author's transl)].
    Hayasaki M; Iwasa SU; Noda K; Yamada Y; Ito K; Iida M; Chin C
    Jpn J Antibiot; 1982 Jan; 35(1):189-201. PubMed ID: 7069930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections.
    Nair SR; Cherubin CE
    Antimicrob Agents Chemother; 1978 Dec; 14(6):866-75. PubMed ID: 742874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteriology of 100 consecutive diabetic foot infections and in vitro susceptibility to ampicillin/sulbactam versus cefoxitin.
    Borrero E; Rossini M
    Angiology; 1992 Apr; 43(4):357-61. PubMed ID: 1558322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefoxitin sodium therapy of anaerobic infections.
    Busch DF; Heseltine PN; Meyer RD; Sutter VL; Finegold SM
    J Antimicrob Chemother; 1978 Jul; 4(B):197-202. PubMed ID: 357386
    [No Abstract]   [Full Text] [Related]  

  • 18. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.
    Talan DA; Summanen PH; Finegold SM
    Clin Infect Dis; 2000 Aug; 31(2):464-71. PubMed ID: 10987706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sporeless anaerobic bacteria with special reference to resistance testing and resistance behavior].
    Wolter M
    Z Arztl Fortbild (Jena); 1983; 77(22):919-23. PubMed ID: 6362224
    [No Abstract]   [Full Text] [Related]  

  • 20. [Infections by anaerobes in children: frequency of isolation and antimicrobial resistance].
    Leaños B; Guiscafré H; Guerra R; Sandoval M; Rubí S; Trejo JA; Zúñiga V
    Bol Med Hosp Infant Mex; 1989 Jul; 46(7):455-62. PubMed ID: 2788434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.